Sugi Predict

Sugi Predict / Compounds / SCHEMBL25317486

SCHEMBL25317486

SCHEMBL25317486

COC(=O)c1ccc2c3c(c(=O)[nH]c2c1C)OCCC3

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.37
▸ GAA P10253 2/20 0.37
▸ GLA P06280 1/20 0.37
▸ GRIA1 P42261 1/20 0.35
▸ GRIA2 P42262 1/20 0.35
▸ GRIA3 P42263 1/20 0.35
▸ GRIA4 P48058 1/20 0.35
▸ HTT P42858 1/20 0.34
▸ MAPT P10636 2/20 0.34
▸ NR4A2 P43354 1/20 0.34
▸ NPC1 O15118 2/20 0.33
▸ PARP1 P09874 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ ALDH1A1 P00352 3/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ HPGD P15428 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29083920 0.83 KDM4E (0.42) KDM4EGAAGLAGRIA1GRIA2
SCHEMBL25315984 0.78 NQO2 (0.33) KDM4EGAAGLAHTTMAPT
SCHEMBL30493725 0.78 NQO2 (0.33) KDM4EGAAGLAHTTMAPT
SCHEMBL30493571 0.76 PARP1 (0.54) KDM4EGAAGLAHTTPARP1
SCHEMBL25314074 0.76 PARP1 (0.54) KDM4EGAAGLAHTTPARP1
SCHEMBL25187778 0.76 KDM4E (0.38) KDM4EGAAGLAGRIA1GRIA2
SCHEMBL30493677 0.75 NQO2 (0.33) KDM4EHTTNPC1ALDH1A1RAB9A
SCHEMBL25318989 0.75 NQO2 (0.33) KDM4EHTTNPC1ALDH1A1RAB9A
SCHEMBL21955361 0.72 KDM4E (0.39) KDM4EGLAHTTMAPTNR4A2
SCHEMBL2916870 0.71 KDM4E (0.47) KDM4EGAAGLAHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250221987-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) 2025-07-10 — — US disclosed
EP-4464704-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Acerand Therapeutics (Hong Kong) Limited (HK) 2024-11-20 — — EP disclosed
WO-2023134647-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 优领医药科技(香港)有限公司 2023-07-20 — — WO disclosed
CN-116425744-A Piperazine-containing ring derivative, pharmaceutically acceptable salt thereof, and preparation method and application thereof 优领医药科技(香港)有限公司 2023-07-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250221987-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF PARP1, PARP11, PARP15 KDM4E 1630/4885GAA 1584/4885GLA 2901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.